Sugi Predict

Sugi Predict / Compounds / SCHEMBL9904807

SCHEMBL9904807

SCHEMBL9904807

Cc1ccc(O)c2c1OCC21CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ ESR1 P03372 4/20 0.33
▸ ESR2 Q92731 4/20 0.33
▸ KDM4E B2RXH2 3/20 0.30
▸ MAPT P10636 3/20 0.30
▸ HPGD P15428 3/20 0.30
▸ RECQL P46063 3/20 0.30
▸ TDP1 Q9NUW8 3/20 0.30
▸ ALDH1A1 P00352 2/20 0.30
▸ CYP3A4 P08684 2/20 0.30
▸ G6PD P11413 2/20 0.30
▸ HSD17B10 Q99714 2/20 0.30
▸ L3MBTL1 Q9Y468 2/20 0.30
▸ MAPK1 P28482 2/20 0.30
▸ NSD2 O96028 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ CASP7 P55210 1/20 0.30
▸ CASP6 P55212 1/20 0.30
▸ MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923814 0.93 ESR1 (0.34) MAOAMAOBESR1ESR2
SCHEMBL17019757 0.85 BRD4 (0.30) —
SCHEMBL16659193 0.84 MAOA (0.35) MAOAMAOBESR1ESR2
SCHEMBL9900562 0.80 ESR1 (0.34) MAOAMAOBESR1ESR2KDM4E
SCHEMBL29438009 0.80 ESR1 (0.34) MAOAMAOBESR1ESR2KDM4E
SCHEMBL17019676 0.78 PDE7A (0.30) —
SCHEMBL19833424 0.76 SLC6A2 (0.32) KDM4EMAPTALDH1A1CYP3A4HSD17B10
SCHEMBL19816134 0.75 ERN1 (0.38) KDM4EL3MBTL1MEN1KMT2A
SCHEMBL16659186 0.74 TP53 (0.38) MAOAMAOBESR1ESR2L3MBTL1
SCHEMBL18199054 0.73 HPGD (0.33) ESR1ESR2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 — — US claimed
US-9422272-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2016-08-23 — — US claimed
EP-2788339-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 — — EP claimed
US-20150336936-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2015-11-26 — — US claimed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 — — EP claimed
US-20140323508-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2014-10-30 — — US claimed
EP-2788339-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2014-10-15 — — EP claimed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US claimed
WO-2013083994-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-06-13 — — WO claimed
EP-4630117-A1 COMPOUNDS FOR THE TREATMENT OF CENTRA NERVOUS SYSTEM DISORDERS Autifony Therapeutics Limited (GB) 2025-10-15 — — EP disclosed
US-20250304564-A1 NOVEL KV3 MODULATORS AUTIFONY THERAPEUTICS LTD (GB) 2025-10-02 — — US disclosed
EP-3947365-B1 SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF BIONOMICS LTD (AU) 2025-10-01 — — EP disclosed
US-12358901-B2 KV3 modulators AUTIFONY THERAPEUTICS LIMITED (GB) 2025-07-15 — — US disclosed
CN-115066424-B Kv3 modulators 奥蒂福尼疗法有限公司 2024-12-27 — — CN disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 — — EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US disclosed
WO-2013083994-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-06-13 — — WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358901-B2 KV3 modulators KCNN3, KCNA3, KCNH3 MAOA 3956/4885MAOB 3289/4885ESR1 2514/4885
US-20150336936-A1 NOVEL COMPOUNDS KCNN3, KCNN2, KCNN1 MAOA 2419/4885MAOB 1263/4885ESR1 4407/4885
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 MAOA 2050/4885MAOB 1907/4885ESR1 4858/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 MAOA 2050/4885MAOB 1907/4885ESR1 4858/4885
US-20140323508-A1 NOVEL COMPOUNDS KCNN3, KCND3, KCNA3 MAOA 2231/4885MAOB 1661/4885ESR1 3101/4885
US-20250304564-A1 NOVEL KV3 MODULATORS KCNN3, KCNA3, KCND3 MAOA 3501/4885MAOB 2740/4885ESR1 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.